These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11841412)

  • 1. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma.
    Liao CA; Lee CM; Wu HC; Wang MC; Lu SN; Eng HL
    Br J Haematol; 2002 Jan; 116(1):166-9. PubMed ID: 11841412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
    Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
    J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
    Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
    J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
    Lee GW; Ryu MH; Lee JL; Oh S; Kim E; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Kim WK; Lee JS; Kang YK
    J Korean Med Sci; 2003 Dec; 18(6):849-54. PubMed ID: 14676442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma.
    Ozguroglu M; Bilici A; Turna H; Serdengecti S
    Med Oncol; 2004; 21(1):67-72. PubMed ID: 15034216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
    Yeo W; Steinberg JL; Tam JS; Chan PK; Leung NW; Lam KC; Mok TS; Johnson PJ
    J Med Virol; 1999 Nov; 59(3):263-9. PubMed ID: 10502254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
    Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
    Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
    van der Eijk AA; Doorduijn JK; Janssen HL; Schalm SW; Niesters HG; de Man RA
    Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1140-4. PubMed ID: 12092307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
    Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.
    Stroffolini T; Andriani A; Bibas M; Barlattani A
    Ann Hematol; 2002 Jan; 81(1):48-9. PubMed ID: 11807636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma.
    Matsuo K; Takenaka K; Shimomura H; Fujii N; Shinagawa K; Kiura K; Harada M
    Leuk Lymphoma; 2001 Mar; 41(1-2):191-5. PubMed ID: 11342373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy of lamivudine in the treatment of reactivation of chronic hepatitis B virus infection in patients on immunosuppressive therapy].
    Popović N; Stojković-Švirtlih N; Simonović-Babić J; Boričić I; Tomanović N; Mitrović N; Delić D
    Srp Arh Celok Lek; 2011; 139(11-12):824-7. PubMed ID: 22338485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
    Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
    Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
    Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.